Torsten O Nielsen

List of Publications by Year in Descending Order

104 papers	**15,303** citations	**42** h-index	**114** g-index
114 ext. papers	**17,797** ext. citations	**8.2** avg, IF	**5.99** L-index

#	Paper	IF	Citations
104	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.. *Nature Communications*, **2022**, 13, 896	17.4	4
103	Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials. *Clinical Cancer Research*, **2021**, 27, 6570-6579	12.9	
102	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. *Journal of the National Cancer Institute*, **2021**, 113, 808-819	9.7	95
101	Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune Checkpoints. *Cancers*, **2021**, 13,	6.6	5
100	A Rapid and Cost-Effective Gene Expression Assay for the Diagnosis of Well-Differentiated and Dedifferentiated Liposarcomas. *Journal of Molecular Diagnostics*, **2021**, 23, 274-284	5.1	4
99	Response to Zhang and Yang. *Journal of the National Cancer Institute*, **2021**, 113, 1597-1598	9.7	2
98	Synovial Sarcoma Oncogenesis Revealed by Single-Cell Profiling. *Trends in Cancer*, **2021**, 7, 482-483	12.5	
97	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. *Breast Cancer Research and Treatment*, **2021**, 185, 557-566	4.4	5
96	Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. *Npj Breast Cancer*, **2021**, 7, 114	7.8	2
95	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. *OncoImmunology*, **2021**, 10, 1924492	7.2	2
94	Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types. *Modern Pathology*, **2020**, 33, 1753-1763	9.8	10
93	Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects.. *Nature Cancer*, **2020**, 1, 518-532	15.4	7
92	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. *Npj Breast Cancer*, **2020**, 6, 15	7.8	8
91	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *Npj Breast Cancer*, **2020**, 6, 17	7.8	54
90	The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients. *Npj Breast Cancer*, **2020**, 6, 7	7.8	9
89	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. *Journal of Pathology*, **2020**, 250, 667-684	9.4	83
88	Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial. *Clinical Cancer Research*, **2020**, 26, 2603-2614	12.9	5

87	Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer. *Clinical Breast Cancer*, **2020**, 20, e423-e432	3	9
86	Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.. *Journal of Clinical Oncology*, **2020**, 38, 510-510	2.2	0
85	Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). *Journal of the National Cancer Institute*, **2020**, 112, 737-746	9.7	30
84	Detection of CSF1 rearrangements deleting the 3ꞱUTR in tenosynovial giant cell tumors. *Genes Chromosomes and Cancer*, **2020**, 59, 96-105	5	12
83	How current assay approval policies are leading to unintended imprecision medicine. *Lancet Oncology, The*, **2020**, 21, 1399-1401	21.7	24
82	Sarcomas: Immune biomarker expression and checkpoint inhibitor trials. *Cancer Treatment Reviews*, **2020**, 91, 102115	14.4	15
81	Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer. *Breast Cancer Research and Treatment*, **2020**, 183, 525-547	4.4	5
80	The epigenomics of sarcoma. *Nature Reviews Cancer*, **2020**, 20, 608-623	31.3	45
79	Phospho-Ser-VCP Is Required for DNA Damage Response and Is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer. *Cell Reports*, **2020**, 31, 107745	10.6	4
78	Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. *Breast Cancer Research and Treatment*, **2020**, 179, 3-10	4.4	21
77	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. *OncoImmunology*, **2020**, 9, 1747340	7.2	49
76	Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development. *Current Oncology Reports*, **2019**, 21, 2	6.3	33
75	The FUS-DDIT3 Interactome in Myxoid Liposarcoma. *Neoplasia*, **2019**, 21, 740-751	6.4	15
74	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. *Histopathology*, **2019**, 75, 225-235	7.3	37
73	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. *Modern Pathology*, **2019**, 32, 59-69	9.8	51
72	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. *Modern Pathology*, **2019**, 32, 1772-1785	9.8	33
71	HDAC2 Regulates Site-Specific Acetylation of MDM2 and Its Ubiquitination Signaling in Tumor Suppression. *IScience*, **2019**, 13, 43-54	6.1	9
70	Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study. *Laboratory Investigation*, **2019**, 99, 107-117	5.9	56

69	Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial. *International Journal of Cancer*, **2019**, 144, 2578-2586	7.5	7
68	The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. *Cancer Cell*, **2018**, 33, 527-541.e8	23.1	55
67	Development and Evaluation of a Pan-Sarcoma Fusion Gene Detection Assay Using the NanoString nCounter Platform. *Journal of Molecular Diagnostics*, **2018**, 20, 63-77	5.1	36
66	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. *Seminars in Cancer Biology*, **2018**, 52, 16-25	12.7	181
65	Emerging targets in cancer immunotherapy. *Seminars in Cancer Biology*, **2018**, 52, 39-52	12.7	164
64	Cell Cycle-Dependent Tumor Engraftment and Migration Are Enabled by Aurora-A. *Molecular Cancer Research*, **2018**, 16, 16-31	6.6	18
63	The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. *Breast Cancer Research*, **2018**, 20, 79	8.3	29
62	The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes. *Acta Oncologica*, **2018**, 57, 44-50	3.2	7
61	Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials. *Acta Oncologica*, **2018**, 57, 135-140	3.2	4
60	Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up. *Breast Cancer Research and Treatment*, **2018**, 168, 107-115	4.4	10
59	TIM-3 expression in breast cancer. *OncoImmunology*, **2018**, 7, e1502128	7.2	34
58	The prognostic effects of somatic mutations in ER-positive breast cancer. *Nature Communications*, **2018**, 9, 3476	17.4	51
57	Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. *Breast Cancer*, **2017**, 24, 3-15	3.4	107
56	Competing Risks of Mortality by PAM50 Intrinsic Subtype of British Columbia Tamoxifen-Treated Cohort of Postmenopausal Patients With Breast Cancer. *Clinical Breast Cancer*, **2017**, 17, e215-e224	3	1
55	An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors. *Journal of Molecular Diagnostics*, **2017**, 19, 147-161	5.1	11
54	Advances in sarcoma diagnostics and treatment. *Oncotarget*, **2017**, 8, 7068-7093	3.3	51
53	Death by HDAC Inhibition in Synovial Sarcoma Cells. *Molecular Cancer Therapeutics*, **2017**, 16, 2656-2667	6.1	21
52	Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncology*, **2017**, 3, e172085	13.4	23

51	High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. *Translational Oncology*, **2017**, 10, 546-554	4.9	8
50	High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. *Clinical Cancer Research*, **2017**, 23, 946-953	12.9	38
49	Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor. *Histopathology*, **2017**, 70, 185-194	7.3	10
48	HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma. *PLoS ONE*, **2017**, 12, e0169407	3.7	26
47	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. *Npj Breast Cancer*, **2016**, 2, 16014	7.8	86
46	Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. *Laboratory Investigation*, **2016**, 96, 885-94	5.9	10
45	Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. *Breast Cancer Research and Treatment*, **2016**, 155, 483-90	4.4	24
44	Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay. *Oncotarget*, **2016**, 7, 34384-94	3.3	10
43	The association between ATG4B and HER2 status in breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, e23275-e23275	2.2	
42	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). *Npj Breast Cancer*, **2016**, 2,	7.8	58
41	Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. *Journal of Pathology*, **2016**, 238, 389-400	9.4	122
40	The genomic landscape of epithelioid sarcoma cell lines and tumours. *Journal of Pathology*, **2016**, 238, 63-73	9.4	27
39	Defining breast cancer intrinsic subtypes by quantitative receptor expression. *Oncologist*, **2015**, 20, 474-82	5.7	102
38	Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. *Journal of Clinical Oncology*, **2015**, 33, 2035-40	2.2	79
37	An international study to increase concordance in Ki67 scoring. *Modern Pathology*, **2015**, 28, 778-86	9.8	168
36	CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping. *Clinical Cancer Research*, **2015**, 21, 1779-81	12.9	14
35	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. *BMC Medical Genomics*, **2015**, 8, 54	3.7	242
34	Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. *Cancer Cell*, **2015**, 28, 500-514	24.3	121

33	New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype. *Clinical Cancer Research*, **2015**, 21, 4753-9	12.9	28
32	NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. *Modern Pathology*, **2015**, 28, 587-95	9.8	47
31	B-crystallin Expression in Breast Cancer is Associated with Brain Metastasis. *Npj Breast Cancer*, **2015**, 1,	7.8	22
30	Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. *Cancer Discovery*, **2015**, 5, 124-34	24.4	107
29	NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. *Journal of Clinical Oncology*, **2015**, 33, 2594-2594	2.2	4
28	Molecular profiling of ER weakly-positive breast cancer.. *Journal of Clinical Oncology*, **2015**, 33, 525-525	2.2	0
27	Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. *BMC Cancer*, **2014**, 14, 177	4.8	199
26	Diagnostic value of next-generation sequencing in an unusual sphenoid tumor. *Oncologist*, **2014**, 19, 623-30	5.7	17
25	Activating transcription factor 2 in mesenchymal tumors. *Human Pathology*, **2014**, 45, 276-84	3.7	12
24	A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. *Modern Pathology*, **2013**, 26, 1438-50	9.8	47
23	An international Ki67 reproducibility study. *Journal of the National Cancer Institute*, **2013**, 105, 1897-906	9.7	398
22	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. *BMC Medical Genomics*, **2012**, 5, 44	3.7	199
21	CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. *Breast Cancer Research*, **2012**, 14, R48	8.3	290
20	Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. *Cancer Cell*, **2012**, 21, 333-47	24.3	116
19	Histone deacetylase 1 and 2 in mesenchymal tumors. *Modern Pathology*, **2012**, 25, 222-30	9.8	29
18	Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. *Journal of the National Cancer Institute*, **2011**, 103, 1656-64	9.7	1156
17	A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. *Clinical Cancer Research*, **2010**, 16, 5222-32	12.9	546
16	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Medicine*, **2010**, 7, e1000279	11.6	616

15	Translating gene expression into clinical care: sarcomas as a paradigm. *Journal of Clinical Oncology*, **2010**, 28, 1796-805	2.2	36
14	Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. *Breast Cancer Research and Treatment*, **2010**, 119, 53-61	4.4	90
13	Discovery research to clinical trial: a ten year journey. *Clinical and Investigative Medicine*, **2010**, 33, E342-8	0.9	4
12	Supervised risk predictor of breast cancer based on intrinsic subtypes. *Journal of Clinical Oncology*, **2009**, 27, 1160-7	2.2	2866
11	Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *Journal of the National Cancer Institute*, **2009**, 101, 736-50	9.7	1545
10	Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. *Breast Cancer Research*, **2008**, 10, R86	8.3	90
9	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. *Clinical Cancer Research*, **2008**, 14, 1368-76	12.9	917
8	Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. *Journal of Clinical Oncology*, **2008**, 26, 5697-704	2.2	230
7	Clinicopathologic factors and nuclear morphometry as independent prognosticators in KIT-positive gastrointestinal stromal tumors. *Journal of Histochemistry and Cytochemistry*, **2008**, 56, 139-45	3.4	11
6	Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. *Journal of Clinical Oncology*, **2006**, 24, 5637-44	2.2	159
5	Microarray analysis of sarcomas. *Advances in Anatomic Pathology*, **2006**, 13, 166-73	5.1	34
4	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clinical Cancer Research*, **2004**, 10, 5367-74	12.9	2156
3	Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. *American Journal of Pathology*, **2003**, 163, 1449-56	5.8	123
2	Molecular characterisation of soft tissue tumours: a gene expression study. *Lancet, The*, **2002**, 359, 1301-7	40	484
1	Circular YAC vectors containing short mammalian origin sequences are maintained under selection as HeLa episomes. *Journal of Cellular Biochemistry*, **2000**, 76, 674-85	4.7	12